nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ABCB1—ovarian cancer	0.288	1	CbGaD
Fluoxetine—ABCB1—Topotecan—ovarian cancer	0.045	0.129	CbGbCtD
Fluoxetine—CYP3A5—Paclitaxel—ovarian cancer	0.0343	0.0979	CbGbCtD
Fluoxetine—ABCB1—Vinorelbine—ovarian cancer	0.0317	0.0906	CbGbCtD
Fluoxetine—CYP2D6—Vinorelbine—ovarian cancer	0.0299	0.0854	CbGbCtD
Fluoxetine—CYP3A4—Topotecan—ovarian cancer	0.027	0.0771	CbGbCtD
Fluoxetine—CYP3A5—Docetaxel—ovarian cancer	0.0248	0.0708	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—ovarian cancer	0.0234	0.067	CbGbCtD
Fluoxetine—CYP2C9—Paclitaxel—ovarian cancer	0.023	0.0656	CbGbCtD
Fluoxetine—ABCB1—Paclitaxel—ovarian cancer	0.0223	0.0637	CbGbCtD
Fluoxetine—CYP3A4—Vinorelbine—ovarian cancer	0.019	0.0543	CbGbCtD
Fluoxetine—ABCB1—Docetaxel—ovarian cancer	0.0161	0.046	CbGbCtD
Fluoxetine—CYP3A4—Paclitaxel—ovarian cancer	0.0134	0.0382	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—ovarian cancer	0.012	0.0343	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—ovarian cancer	0.0113	0.0323	CbGbCtD
Fluoxetine—CYP3A4—Docetaxel—ovarian cancer	0.00966	0.0276	CbGbCtD
Fluoxetine—CYP3A4—Doxorubicin—ovarian cancer	0.0072	0.0206	CbGbCtD
Fluoxetine—HTR2A—vein—ovarian cancer	0.00307	0.104	CbGeAlD
Fluoxetine—SIGMAR1—myometrium—ovarian cancer	0.00114	0.0385	CbGeAlD
Fluoxetine—ORM1—endometrium—ovarian cancer	0.000944	0.032	CbGeAlD
Fluoxetine—SIGMAR1—uterine cervix—ovarian cancer	0.000884	0.0299	CbGeAlD
Fluoxetine—SIGMAR1—decidua—ovarian cancer	0.000842	0.0285	CbGeAlD
Fluoxetine—SIGMAR1—endometrium—ovarian cancer	0.000799	0.0271	CbGeAlD
Fluoxetine—ORM1—female reproductive system—ovarian cancer	0.000782	0.0265	CbGeAlD
Fluoxetine—SLC6A2—decidua—ovarian cancer	0.000746	0.0253	CbGeAlD
Fluoxetine—ORM1—bone marrow—ovarian cancer	0.000739	0.025	CbGeAlD
Fluoxetine—SIGMAR1—uterus—ovarian cancer	0.000736	0.0249	CbGeAlD
Fluoxetine—HTR2C—female reproductive system—ovarian cancer	0.000703	0.0238	CbGeAlD
Fluoxetine—SLC6A4—female reproductive system—ovarian cancer	0.000667	0.0226	CbGeAlD
Fluoxetine—SLC6A2—gonad—ovarian cancer	0.000657	0.0223	CbGeAlD
Fluoxetine—SIGMAR1—bone marrow—ovarian cancer	0.000625	0.0212	CbGeAlD
Fluoxetine—SIGMAR1—female gonad—ovarian cancer	0.000602	0.0204	CbGeAlD
Fluoxetine—SIGMAR1—vagina—ovarian cancer	0.000599	0.0203	CbGeAlD
Fluoxetine—SLC6A2—female reproductive system—ovarian cancer	0.000587	0.0199	CbGeAlD
Fluoxetine—HTR2A—embryo—ovarian cancer	0.000582	0.0197	CbGeAlD
Fluoxetine—CYP3A5—uterine cervix—ovarian cancer	0.000581	0.0197	CbGeAlD
Fluoxetine—ALB—testis—ovarian cancer	0.000554	0.0188	CbGeAlD
Fluoxetine—SIGMAR1—testis—ovarian cancer	0.000534	0.0181	CbGeAlD
Fluoxetine—CYP2C19—vagina—ovarian cancer	0.0005	0.0169	CbGeAlD
Fluoxetine—CYP2B6—gonad—ovarian cancer	0.000484	0.0164	CbGeAlD
Fluoxetine—HTR2A—epithelium—ovarian cancer	0.000475	0.0161	CbGeAlD
Fluoxetine—SLC6A2—testis—ovarian cancer	0.000474	0.016	CbGeAlD
Fluoxetine—ORM1—lymph node—ovarian cancer	0.000458	0.0155	CbGeAlD
Fluoxetine—CYP2B6—female reproductive system—ovarian cancer	0.000432	0.0146	CbGeAlD
Fluoxetine—CYP2C9—female reproductive system—ovarian cancer	0.000428	0.0145	CbGeAlD
Fluoxetine—ALB—lymph node—ovarian cancer	0.000401	0.0136	CbGeAlD
Fluoxetine—ABCB1—myometrium—ovarian cancer	0.000396	0.0134	CbGeAlD
Fluoxetine—CYP3A5—female gonad—ovarian cancer	0.000396	0.0134	CbGeAlD
Fluoxetine—HTR2A—gonad—ovarian cancer	0.000395	0.0134	CbGeAlD
Fluoxetine—CYP3A5—vagina—ovarian cancer	0.000394	0.0133	CbGeAlD
Fluoxetine—CYP2B6—vagina—ovarian cancer	0.000391	0.0132	CbGeAlD
Fluoxetine—SIGMAR1—lymph node—ovarian cancer	0.000387	0.0131	CbGeAlD
Fluoxetine—ABCB1—embryo—ovarian cancer	0.000381	0.0129	CbGeAlD
Fluoxetine—HTR2A—female reproductive system—ovarian cancer	0.000353	0.0119	CbGeAlD
Fluoxetine—CYP2B6—testis—ovarian cancer	0.000349	0.0118	CbGeAlD
Fluoxetine—SLC6A2—lymph node—ovarian cancer	0.000343	0.0116	CbGeAlD
Fluoxetine—CYP3A4—female reproductive system—ovarian cancer	0.000327	0.0111	CbGeAlD
Fluoxetine—CYP2D6—female reproductive system—ovarian cancer	0.000321	0.0109	CbGeAlD
Fluoxetine—HTR2A—vagina—ovarian cancer	0.000319	0.0108	CbGeAlD
Fluoxetine—ABCB1—epithelium—ovarian cancer	0.000311	0.0105	CbGeAlD
Fluoxetine—ABCB1—uterine cervix—ovarian cancer	0.000309	0.0105	CbGeAlD
Fluoxetine—ABCB1—decidua—ovarian cancer	0.000294	0.00996	CbGeAlD
Fluoxetine—CYP2D6—female gonad—ovarian cancer	0.000292	0.00991	CbGeAlD
Fluoxetine—HTR2A—testis—ovarian cancer	0.000285	0.00964	CbGeAlD
Fluoxetine—ABCB1—endometrium—ovarian cancer	0.000279	0.00945	CbGeAlD
Fluoxetine—CYP2D6—testis—ovarian cancer	0.000259	0.00879	CbGeAlD
Fluoxetine—ABCB1—gonad—ovarian cancer	0.000259	0.00877	CbGeAlD
Fluoxetine—ABCB1—uterus—ovarian cancer	0.000257	0.00871	CbGeAlD
Fluoxetine—ABCB1—female reproductive system—ovarian cancer	0.000231	0.00783	CbGeAlD
Fluoxetine—ABCB1—bone marrow—ovarian cancer	0.000218	0.00739	CbGeAlD
Fluoxetine—ABCB1—female gonad—ovarian cancer	0.00021	0.00713	CbGeAlD
Fluoxetine—ABCB1—vagina—ovarian cancer	0.000209	0.00708	CbGeAlD
Fluoxetine—ABCB1—testis—ovarian cancer	0.000187	0.00632	CbGeAlD
Fluoxetine—ABCB1—lymph node—ovarian cancer	0.000135	0.00458	CbGeAlD
Fluoxetine—Bronchitis—Doxorubicin—ovarian cancer	0.000112	0.000354	CcSEcCtD
Fluoxetine—Dyspnoea—Paclitaxel—ovarian cancer	0.000112	0.000353	CcSEcCtD
Fluoxetine—Somnolence—Paclitaxel—ovarian cancer	0.000111	0.000352	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000111	0.000351	CcSEcCtD
Fluoxetine—Myalgia—Docetaxel—ovarian cancer	0.000111	0.00035	CcSEcCtD
Fluoxetine—Chest pain—Docetaxel—ovarian cancer	0.000111	0.00035	CcSEcCtD
Fluoxetine—Arthralgia—Docetaxel—ovarian cancer	0.000111	0.00035	CcSEcCtD
Fluoxetine—Pancytopenia—Doxorubicin—ovarian cancer	0.000111	0.000349	CcSEcCtD
Fluoxetine—Nausea—Vinorelbine—ovarian cancer	0.000111	0.000349	CcSEcCtD
Fluoxetine—Renal failure—Epirubicin—ovarian cancer	0.00011	0.000348	CcSEcCtD
Fluoxetine—Dyspepsia—Paclitaxel—ovarian cancer	0.00011	0.000348	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.00011	0.000347	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00011	0.000347	CcSEcCtD
Fluoxetine—Jaundice—Epirubicin—ovarian cancer	0.00011	0.000346	CcSEcCtD
Fluoxetine—Stomatitis—Epirubicin—ovarian cancer	0.00011	0.000346	CcSEcCtD
Fluoxetine—Conjunctivitis—Epirubicin—ovarian cancer	0.000109	0.000345	CcSEcCtD
Fluoxetine—Urinary tract infection—Epirubicin—ovarian cancer	0.000109	0.000345	CcSEcCtD
Fluoxetine—Dysuria—Doxorubicin—ovarian cancer	0.000109	0.000344	CcSEcCtD
Fluoxetine—Decreased appetite—Paclitaxel—ovarian cancer	0.000109	0.000344	CcSEcCtD
Fluoxetine—Dry mouth—Docetaxel—ovarian cancer	0.000108	0.000342	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000108	0.000342	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000108	0.000341	CcSEcCtD
Fluoxetine—Fatigue—Paclitaxel—ovarian cancer	0.000108	0.000341	CcSEcCtD
Fluoxetine—Sweating—Epirubicin—ovarian cancer	0.000108	0.00034	CcSEcCtD
Fluoxetine—Pollakiuria—Doxorubicin—ovarian cancer	0.000108	0.00034	CcSEcCtD
Fluoxetine—Constipation—Paclitaxel—ovarian cancer	0.000107	0.000338	CcSEcCtD
Fluoxetine—Pain—Paclitaxel—ovarian cancer	0.000107	0.000338	CcSEcCtD
Fluoxetine—Haematuria—Epirubicin—ovarian cancer	0.000107	0.000338	CcSEcCtD
Fluoxetine—Confusional state—Docetaxel—ovarian cancer	0.000107	0.000338	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000106	0.000336	CcSEcCtD
Fluoxetine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000106	0.000335	CcSEcCtD
Fluoxetine—Weight increased—Doxorubicin—ovarian cancer	0.000106	0.000335	CcSEcCtD
Fluoxetine—Epistaxis—Epirubicin—ovarian cancer	0.000106	0.000334	CcSEcCtD
Fluoxetine—Infection—Docetaxel—ovarian cancer	0.000106	0.000333	CcSEcCtD
Fluoxetine—Weight decreased—Doxorubicin—ovarian cancer	0.000106	0.000333	CcSEcCtD
Fluoxetine—Sinusitis—Epirubicin—ovarian cancer	0.000105	0.000333	CcSEcCtD
Fluoxetine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000105	0.000332	CcSEcCtD
Fluoxetine—Pneumonia—Doxorubicin—ovarian cancer	0.000105	0.00033	CcSEcCtD
Fluoxetine—Shock—Docetaxel—ovarian cancer	0.000105	0.00033	CcSEcCtD
Fluoxetine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000104	0.000328	CcSEcCtD
Fluoxetine—Drowsiness—Doxorubicin—ovarian cancer	0.000104	0.000328	CcSEcCtD
Fluoxetine—Tachycardia—Docetaxel—ovarian cancer	0.000104	0.000327	CcSEcCtD
Fluoxetine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000103	0.000326	CcSEcCtD
Fluoxetine—Skin disorder—Docetaxel—ovarian cancer	0.000103	0.000326	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000103	0.000325	CcSEcCtD
Fluoxetine—Bradycardia—Epirubicin—ovarian cancer	0.000103	0.000324	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000103	0.000323	CcSEcCtD
Fluoxetine—Renal failure—Doxorubicin—ovarian cancer	0.000102	0.000322	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000102	0.000321	CcSEcCtD
Fluoxetine—Haemoglobin—Epirubicin—ovarian cancer	0.000101	0.00032	CcSEcCtD
Fluoxetine—Jaundice—Doxorubicin—ovarian cancer	0.000101	0.00032	CcSEcCtD
Fluoxetine—Stomatitis—Doxorubicin—ovarian cancer	0.000101	0.00032	CcSEcCtD
Fluoxetine—Anorexia—Docetaxel—ovarian cancer	0.000101	0.000319	CcSEcCtD
Fluoxetine—Rhinitis—Epirubicin—ovarian cancer	0.000101	0.000319	CcSEcCtD
Fluoxetine—Conjunctivitis—Doxorubicin—ovarian cancer	0.000101	0.000319	CcSEcCtD
Fluoxetine—Urinary tract infection—Doxorubicin—ovarian cancer	0.000101	0.000319	CcSEcCtD
Fluoxetine—Haemorrhage—Epirubicin—ovarian cancer	0.000101	0.000318	CcSEcCtD
Fluoxetine—Hepatitis—Epirubicin—ovarian cancer	0.000101	0.000318	CcSEcCtD
Fluoxetine—Hypoaesthesia—Epirubicin—ovarian cancer	0.0001	0.000317	CcSEcCtD
Fluoxetine—Pharyngitis—Epirubicin—ovarian cancer	0.0001	0.000316	CcSEcCtD
Fluoxetine—Sweating—Doxorubicin—ovarian cancer	9.97e-05	0.000314	CcSEcCtD
Fluoxetine—Urticaria—Paclitaxel—ovarian cancer	9.96e-05	0.000314	CcSEcCtD
Fluoxetine—Oedema peripheral—Epirubicin—ovarian cancer	9.94e-05	0.000313	CcSEcCtD
Fluoxetine—Hypotension—Docetaxel—ovarian cancer	9.93e-05	0.000313	CcSEcCtD
Fluoxetine—Haematuria—Doxorubicin—ovarian cancer	9.92e-05	0.000313	CcSEcCtD
Fluoxetine—Abdominal pain—Paclitaxel—ovarian cancer	9.91e-05	0.000313	CcSEcCtD
Fluoxetine—Body temperature increased—Paclitaxel—ovarian cancer	9.91e-05	0.000313	CcSEcCtD
Fluoxetine—Epistaxis—Doxorubicin—ovarian cancer	9.81e-05	0.000309	CcSEcCtD
Fluoxetine—Sinusitis—Doxorubicin—ovarian cancer	9.76e-05	0.000308	CcSEcCtD
Fluoxetine—Visual impairment—Epirubicin—ovarian cancer	9.72e-05	0.000307	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	9.68e-05	0.000305	CcSEcCtD
Fluoxetine—Insomnia—Docetaxel—ovarian cancer	9.61e-05	0.000303	CcSEcCtD
Fluoxetine—Paraesthesia—Docetaxel—ovarian cancer	9.54e-05	0.000301	CcSEcCtD
Fluoxetine—Erythema multiforme—Epirubicin—ovarian cancer	9.54e-05	0.000301	CcSEcCtD
Fluoxetine—Bradycardia—Doxorubicin—ovarian cancer	9.5e-05	0.0003	CcSEcCtD
Fluoxetine—Dyspnoea—Docetaxel—ovarian cancer	9.47e-05	0.000299	CcSEcCtD
Fluoxetine—Somnolence—Docetaxel—ovarian cancer	9.45e-05	0.000298	CcSEcCtD
Fluoxetine—Tinnitus—Epirubicin—ovarian cancer	9.41e-05	0.000297	CcSEcCtD
Fluoxetine—Haemoglobin—Doxorubicin—ovarian cancer	9.38e-05	0.000296	CcSEcCtD
Fluoxetine—Rhinitis—Doxorubicin—ovarian cancer	9.36e-05	0.000295	CcSEcCtD
Fluoxetine—Dyspepsia—Docetaxel—ovarian cancer	9.35e-05	0.000295	CcSEcCtD
Fluoxetine—Hepatitis—Doxorubicin—ovarian cancer	9.34e-05	0.000294	CcSEcCtD
Fluoxetine—Haemorrhage—Doxorubicin—ovarian cancer	9.34e-05	0.000294	CcSEcCtD
Fluoxetine—Hypoaesthesia—Doxorubicin—ovarian cancer	9.29e-05	0.000293	CcSEcCtD
Fluoxetine—Pharyngitis—Doxorubicin—ovarian cancer	9.27e-05	0.000292	CcSEcCtD
Fluoxetine—Decreased appetite—Docetaxel—ovarian cancer	9.24e-05	0.000291	CcSEcCtD
Fluoxetine—Hypersensitivity—Paclitaxel—ovarian cancer	9.24e-05	0.000291	CcSEcCtD
Fluoxetine—Oedema peripheral—Doxorubicin—ovarian cancer	9.2e-05	0.00029	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Docetaxel—ovarian cancer	9.18e-05	0.000289	CcSEcCtD
Fluoxetine—Fatigue—Docetaxel—ovarian cancer	9.16e-05	0.000289	CcSEcCtD
Fluoxetine—Pain—Docetaxel—ovarian cancer	9.09e-05	0.000287	CcSEcCtD
Fluoxetine—Constipation—Docetaxel—ovarian cancer	9.09e-05	0.000287	CcSEcCtD
Fluoxetine—Chills—Epirubicin—ovarian cancer	9.05e-05	0.000286	CcSEcCtD
Fluoxetine—Arrhythmia—Epirubicin—ovarian cancer	9.01e-05	0.000284	CcSEcCtD
Fluoxetine—Visual impairment—Doxorubicin—ovarian cancer	9e-05	0.000284	CcSEcCtD
Fluoxetine—Asthenia—Paclitaxel—ovarian cancer	9e-05	0.000284	CcSEcCtD
Fluoxetine—Alopecia—Epirubicin—ovarian cancer	8.92e-05	0.000281	CcSEcCtD
Fluoxetine—Pruritus—Paclitaxel—ovarian cancer	8.87e-05	0.00028	CcSEcCtD
Fluoxetine—Mental disorder—Epirubicin—ovarian cancer	8.84e-05	0.000279	CcSEcCtD
Fluoxetine—Erythema multiforme—Doxorubicin—ovarian cancer	8.83e-05	0.000278	CcSEcCtD
Fluoxetine—Malnutrition—Epirubicin—ovarian cancer	8.78e-05	0.000277	CcSEcCtD
Fluoxetine—Feeling abnormal—Docetaxel—ovarian cancer	8.76e-05	0.000276	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—ovarian cancer	8.7e-05	0.000275	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Docetaxel—ovarian cancer	8.69e-05	0.000274	CcSEcCtD
Fluoxetine—Flatulence—Epirubicin—ovarian cancer	8.65e-05	0.000273	CcSEcCtD
Fluoxetine—Tension—Epirubicin—ovarian cancer	8.62e-05	0.000272	CcSEcCtD
Fluoxetine—Dysgeusia—Epirubicin—ovarian cancer	8.6e-05	0.000271	CcSEcCtD
Fluoxetine—Diarrhoea—Paclitaxel—ovarian cancer	8.58e-05	0.000271	CcSEcCtD
Fluoxetine—Nervousness—Epirubicin—ovarian cancer	8.53e-05	0.000269	CcSEcCtD
Fluoxetine—Back pain—Epirubicin—ovarian cancer	8.5e-05	0.000268	CcSEcCtD
Fluoxetine—Muscle spasms—Epirubicin—ovarian cancer	8.44e-05	0.000266	CcSEcCtD
Fluoxetine—Abdominal pain—Docetaxel—ovarian cancer	8.4e-05	0.000265	CcSEcCtD
Fluoxetine—Body temperature increased—Docetaxel—ovarian cancer	8.4e-05	0.000265	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—ovarian cancer	8.38e-05	0.000264	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—ovarian cancer	8.34e-05	0.000263	CcSEcCtD
Fluoxetine—Dizziness—Paclitaxel—ovarian cancer	8.29e-05	0.000261	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—ovarian cancer	8.25e-05	0.00026	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—ovarian cancer	8.18e-05	0.000258	CcSEcCtD
Fluoxetine—Ill-defined disorder—Epirubicin—ovarian cancer	8.15e-05	0.000257	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—ovarian cancer	8.13e-05	0.000256	CcSEcCtD
Fluoxetine—Anaemia—Epirubicin—ovarian cancer	8.12e-05	0.000256	CcSEcCtD
Fluoxetine—Agitation—Epirubicin—ovarian cancer	8.07e-05	0.000255	CcSEcCtD
Fluoxetine—Flatulence—Doxorubicin—ovarian cancer	8.01e-05	0.000253	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—ovarian cancer	7.97e-05	0.000252	CcSEcCtD
Fluoxetine—Vomiting—Paclitaxel—ovarian cancer	7.97e-05	0.000251	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—ovarian cancer	7.96e-05	0.000251	CcSEcCtD
Fluoxetine—Malaise—Epirubicin—ovarian cancer	7.92e-05	0.00025	CcSEcCtD
Fluoxetine—Rash—Paclitaxel—ovarian cancer	7.91e-05	0.000249	CcSEcCtD
Fluoxetine—Dermatitis—Paclitaxel—ovarian cancer	7.9e-05	0.000249	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—ovarian cancer	7.89e-05	0.000249	CcSEcCtD
Fluoxetine—Vertigo—Epirubicin—ovarian cancer	7.89e-05	0.000249	CcSEcCtD
Fluoxetine—Syncope—Epirubicin—ovarian cancer	7.88e-05	0.000248	CcSEcCtD
Fluoxetine—Leukopenia—Epirubicin—ovarian cancer	7.86e-05	0.000248	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—ovarian cancer	7.86e-05	0.000248	CcSEcCtD
Fluoxetine—Headache—Paclitaxel—ovarian cancer	7.85e-05	0.000248	CcSEcCtD
Fluoxetine—Hypersensitivity—Docetaxel—ovarian cancer	7.83e-05	0.000247	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—ovarian cancer	7.81e-05	0.000246	CcSEcCtD
Fluoxetine—Palpitations—Epirubicin—ovarian cancer	7.76e-05	0.000245	CcSEcCtD
Fluoxetine—Loss of consciousness—Epirubicin—ovarian cancer	7.72e-05	0.000243	CcSEcCtD
Fluoxetine—Cough—Epirubicin—ovarian cancer	7.66e-05	0.000242	CcSEcCtD
Fluoxetine—Asthenia—Docetaxel—ovarian cancer	7.62e-05	0.00024	CcSEcCtD
Fluoxetine—Convulsion—Epirubicin—ovarian cancer	7.61e-05	0.00024	CcSEcCtD
Fluoxetine—Hypertension—Epirubicin—ovarian cancer	7.58e-05	0.000239	CcSEcCtD
Fluoxetine—Ill-defined disorder—Doxorubicin—ovarian cancer	7.54e-05	0.000238	CcSEcCtD
Fluoxetine—Pruritus—Docetaxel—ovarian cancer	7.52e-05	0.000237	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—ovarian cancer	7.51e-05	0.000237	CcSEcCtD
Fluoxetine—Chest pain—Epirubicin—ovarian cancer	7.48e-05	0.000236	CcSEcCtD
Fluoxetine—Arthralgia—Epirubicin—ovarian cancer	7.48e-05	0.000236	CcSEcCtD
Fluoxetine—Myalgia—Epirubicin—ovarian cancer	7.48e-05	0.000236	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—ovarian cancer	7.47e-05	0.000236	CcSEcCtD
Fluoxetine—Anxiety—Epirubicin—ovarian cancer	7.45e-05	0.000235	CcSEcCtD
Fluoxetine—Nausea—Paclitaxel—ovarian cancer	7.45e-05	0.000235	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	7.43e-05	0.000234	CcSEcCtD
Fluoxetine—Discomfort—Epirubicin—ovarian cancer	7.39e-05	0.000233	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—ovarian cancer	7.33e-05	0.000231	CcSEcCtD
Fluoxetine—Dry mouth—Epirubicin—ovarian cancer	7.31e-05	0.000231	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—ovarian cancer	7.3e-05	0.00023	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—ovarian cancer	7.29e-05	0.00023	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—ovarian cancer	7.27e-05	0.000229	CcSEcCtD
Fluoxetine—Diarrhoea—Docetaxel—ovarian cancer	7.27e-05	0.000229	CcSEcCtD
Fluoxetine—Confusional state—Epirubicin—ovarian cancer	7.23e-05	0.000228	CcSEcCtD
Fluoxetine—Palpitations—Doxorubicin—ovarian cancer	7.18e-05	0.000227	CcSEcCtD
Fluoxetine—Anaphylactic shock—Epirubicin—ovarian cancer	7.17e-05	0.000226	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—ovarian cancer	7.14e-05	0.000225	CcSEcCtD
Fluoxetine—Infection—Epirubicin—ovarian cancer	7.12e-05	0.000225	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—ovarian cancer	7.09e-05	0.000224	CcSEcCtD
Fluoxetine—Shock—Epirubicin—ovarian cancer	7.05e-05	0.000222	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—ovarian cancer	7.04e-05	0.000222	CcSEcCtD
Fluoxetine—Dizziness—Docetaxel—ovarian cancer	7.03e-05	0.000222	CcSEcCtD
Fluoxetine—Thrombocytopenia—Epirubicin—ovarian cancer	7.02e-05	0.000221	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—ovarian cancer	7.02e-05	0.000221	CcSEcCtD
Fluoxetine—Tachycardia—Epirubicin—ovarian cancer	7e-05	0.000221	CcSEcCtD
Fluoxetine—Skin disorder—Epirubicin—ovarian cancer	6.96e-05	0.00022	CcSEcCtD
Fluoxetine—Hyperhidrosis—Epirubicin—ovarian cancer	6.93e-05	0.000219	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—ovarian cancer	6.92e-05	0.000218	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—ovarian cancer	6.92e-05	0.000218	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—ovarian cancer	6.92e-05	0.000218	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—ovarian cancer	6.89e-05	0.000217	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.87e-05	0.000217	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—ovarian cancer	6.84e-05	0.000216	CcSEcCtD
Fluoxetine—Anorexia—Epirubicin—ovarian cancer	6.83e-05	0.000215	CcSEcCtD
Fluoxetine—Dry mouth—Doxorubicin—ovarian cancer	6.77e-05	0.000213	CcSEcCtD
Fluoxetine—Vomiting—Docetaxel—ovarian cancer	6.76e-05	0.000213	CcSEcCtD
Fluoxetine—Rash—Docetaxel—ovarian cancer	6.7e-05	0.000211	CcSEcCtD
Fluoxetine—Hypotension—Epirubicin—ovarian cancer	6.7e-05	0.000211	CcSEcCtD
Fluoxetine—Dermatitis—Docetaxel—ovarian cancer	6.69e-05	0.000211	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—ovarian cancer	6.69e-05	0.000211	CcSEcCtD
Fluoxetine—Headache—Docetaxel—ovarian cancer	6.66e-05	0.00021	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—ovarian cancer	6.63e-05	0.000209	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—ovarian cancer	6.59e-05	0.000208	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	6.53e-05	0.000206	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—ovarian cancer	6.53e-05	0.000206	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—ovarian cancer	6.49e-05	0.000205	CcSEcCtD
Fluoxetine—Insomnia—Epirubicin—ovarian cancer	6.48e-05	0.000204	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—ovarian cancer	6.47e-05	0.000204	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—ovarian cancer	6.44e-05	0.000203	CcSEcCtD
Fluoxetine—Paraesthesia—Epirubicin—ovarian cancer	6.44e-05	0.000203	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—ovarian cancer	6.41e-05	0.000202	CcSEcCtD
Fluoxetine—Dyspnoea—Epirubicin—ovarian cancer	6.39e-05	0.000202	CcSEcCtD
Fluoxetine—Somnolence—Epirubicin—ovarian cancer	6.37e-05	0.000201	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—ovarian cancer	6.32e-05	0.000199	CcSEcCtD
Fluoxetine—Nausea—Docetaxel—ovarian cancer	6.31e-05	0.000199	CcSEcCtD
Fluoxetine—Dyspepsia—Epirubicin—ovarian cancer	6.31e-05	0.000199	CcSEcCtD
Fluoxetine—Decreased appetite—Epirubicin—ovarian cancer	6.23e-05	0.000197	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—ovarian cancer	6.2e-05	0.000195	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Epirubicin—ovarian cancer	6.19e-05	0.000195	CcSEcCtD
Fluoxetine—Fatigue—Epirubicin—ovarian cancer	6.18e-05	0.000195	CcSEcCtD
Fluoxetine—Pain—Epirubicin—ovarian cancer	6.13e-05	0.000193	CcSEcCtD
Fluoxetine—Constipation—Epirubicin—ovarian cancer	6.13e-05	0.000193	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	6.04e-05	0.000191	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—ovarian cancer	6e-05	0.000189	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—ovarian cancer	5.96e-05	0.000188	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—ovarian cancer	5.91e-05	0.000186	CcSEcCtD
Fluoxetine—Feeling abnormal—Epirubicin—ovarian cancer	5.91e-05	0.000186	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—ovarian cancer	5.9e-05	0.000186	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Epirubicin—ovarian cancer	5.86e-05	0.000185	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—ovarian cancer	5.84e-05	0.000184	CcSEcCtD
Fluoxetine—Decreased appetite—Doxorubicin—ovarian cancer	5.77e-05	0.000182	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.73e-05	0.000181	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—ovarian cancer	5.72e-05	0.00018	CcSEcCtD
Fluoxetine—Urticaria—Epirubicin—ovarian cancer	5.69e-05	0.00018	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—ovarian cancer	5.67e-05	0.000179	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—ovarian cancer	5.67e-05	0.000179	CcSEcCtD
Fluoxetine—Abdominal pain—Epirubicin—ovarian cancer	5.67e-05	0.000179	CcSEcCtD
Fluoxetine—Body temperature increased—Epirubicin—ovarian cancer	5.67e-05	0.000179	CcSEcCtD
Fluoxetine—Feeling abnormal—Doxorubicin—ovarian cancer	5.47e-05	0.000172	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.42e-05	0.000171	CcSEcCtD
Fluoxetine—Hypersensitivity—Epirubicin—ovarian cancer	5.28e-05	0.000167	CcSEcCtD
Fluoxetine—Urticaria—Doxorubicin—ovarian cancer	5.27e-05	0.000166	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—ovarian cancer	5.24e-05	0.000165	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—ovarian cancer	5.24e-05	0.000165	CcSEcCtD
Fluoxetine—Asthenia—Epirubicin—ovarian cancer	5.14e-05	0.000162	CcSEcCtD
Fluoxetine—Pruritus—Epirubicin—ovarian cancer	5.07e-05	0.00016	CcSEcCtD
Fluoxetine—Diarrhoea—Epirubicin—ovarian cancer	4.9e-05	0.000155	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—ovarian cancer	4.89e-05	0.000154	CcSEcCtD
Fluoxetine—Asthenia—Doxorubicin—ovarian cancer	4.76e-05	0.00015	CcSEcCtD
Fluoxetine—Dizziness—Epirubicin—ovarian cancer	4.74e-05	0.000149	CcSEcCtD
Fluoxetine—Pruritus—Doxorubicin—ovarian cancer	4.69e-05	0.000148	CcSEcCtD
Fluoxetine—Vomiting—Epirubicin—ovarian cancer	4.56e-05	0.000144	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—ovarian cancer	4.54e-05	0.000143	CcSEcCtD
Fluoxetine—Rash—Epirubicin—ovarian cancer	4.52e-05	0.000143	CcSEcCtD
Fluoxetine—Dermatitis—Epirubicin—ovarian cancer	4.52e-05	0.000142	CcSEcCtD
Fluoxetine—Headache—Epirubicin—ovarian cancer	4.49e-05	0.000142	CcSEcCtD
Fluoxetine—Dizziness—Doxorubicin—ovarian cancer	4.39e-05	0.000138	CcSEcCtD
Fluoxetine—Nausea—Epirubicin—ovarian cancer	4.26e-05	0.000134	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—ovarian cancer	4.22e-05	0.000133	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—ovarian cancer	4.18e-05	0.000132	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—ovarian cancer	4.18e-05	0.000132	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—ovarian cancer	4.16e-05	0.000131	CcSEcCtD
Fluoxetine—Nausea—Doxorubicin—ovarian cancer	3.94e-05	0.000124	CcSEcCtD
Fluoxetine—CYP2D6—Metabolism—YAP1—ovarian cancer	5.09e-06	0.000328	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—YAP1—ovarian cancer	5.05e-06	0.000325	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—FASN—ovarian cancer	5.03e-06	0.000323	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CXCL8—ovarian cancer	5e-06	0.000322	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.99e-06	0.000321	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—BRIP1—ovarian cancer	4.96e-06	0.000319	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPP1CC—ovarian cancer	4.96e-06	0.000319	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	4.96e-06	0.000319	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—SLC5A5—ovarian cancer	4.94e-06	0.000318	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.89e-06	0.000314	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	4.82e-06	0.00031	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.82e-06	0.00031	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—IL2—ovarian cancer	4.78e-06	0.000308	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—SLC2A1—ovarian cancer	4.78e-06	0.000307	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PPP2R1A—ovarian cancer	4.73e-06	0.000304	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CB—ovarian cancer	4.73e-06	0.000304	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IL2—ovarian cancer	4.72e-06	0.000304	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	4.71e-06	0.000303	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CD—ovarian cancer	4.71e-06	0.000303	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.69e-06	0.000302	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.68e-06	0.000301	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP1B1—ovarian cancer	4.58e-06	0.000295	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CXCL8—ovarian cancer	4.54e-06	0.000292	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CB—ovarian cancer	4.52e-06	0.000291	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—FASN—ovarian cancer	4.51e-06	0.00029	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ABCB1—ovarian cancer	4.48e-06	0.000288	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—SLC5A5—ovarian cancer	4.44e-06	0.000286	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—FASN—ovarian cancer	4.4e-06	0.000283	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—TYMS—ovarian cancer	4.4e-06	0.000283	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.39e-06	0.000283	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ABCB1—ovarian cancer	4.38e-06	0.000282	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CXCL8—ovarian cancer	4.34e-06	0.00028	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL2—ovarian cancer	4.34e-06	0.000279	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—SLC5A5—ovarian cancer	4.33e-06	0.000279	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TERT—ovarian cancer	4.33e-06	0.000278	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—YAP1—ovarian cancer	4.31e-06	0.000278	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—TYMS—ovarian cancer	4.3e-06	0.000277	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—SLC2A1—ovarian cancer	4.29e-06	0.000276	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.27e-06	0.000275	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.2e-06	0.00027	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—SLC2A1—ovarian cancer	4.18e-06	0.000269	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—IL2—ovarian cancer	4.15e-06	0.000267	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—FASN—ovarian cancer	4.15e-06	0.000267	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—FASN—ovarian cancer	4.11e-06	0.000265	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP1B1—ovarian cancer	4.11e-06	0.000264	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CB—ovarian cancer	4.11e-06	0.000264	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	4.08e-06	0.000263	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPP2R1A—ovarian cancer	4.06e-06	0.000261	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SLC5A5—ovarian cancer	4.05e-06	0.00026	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.04e-06	0.00026	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP1B1—ovarian cancer	4.01e-06	0.000258	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—ovarian cancer	4.01e-06	0.000258	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CAV1—ovarian cancer	4e-06	0.000257	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—NRAS—ovarian cancer	3.96e-06	0.000255	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCL8—ovarian cancer	3.95e-06	0.000254	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	3.94e-06	0.000254	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—SLC2A1—ovarian cancer	3.91e-06	0.000252	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ESR1—ovarian cancer	3.86e-06	0.000248	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.83e-06	0.000246	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6ST—ovarian cancer	3.79e-06	0.000244	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK3—ovarian cancer	3.79e-06	0.000244	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	3.78e-06	0.000243	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL2—ovarian cancer	3.77e-06	0.000243	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ABCB1—ovarian cancer	3.77e-06	0.000243	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TERT—ovarian cancer	3.76e-06	0.000242	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.75e-06	0.000241	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1B1—ovarian cancer	3.75e-06	0.000241	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—TYMS—ovarian cancer	3.7e-06	0.000238	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	3.64e-06	0.000235	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CG—ovarian cancer	3.64e-06	0.000235	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APC—ovarian cancer	3.64e-06	0.000235	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—NRAS—ovarian cancer	3.64e-06	0.000235	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.63e-06	0.000233	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK1—ovarian cancer	3.61e-06	0.000232	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPP2R1A—ovarian cancer	3.56e-06	0.000229	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CAV1—ovarian cancer	3.54e-06	0.000228	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—FASN—ovarian cancer	3.52e-06	0.000226	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK3—ovarian cancer	3.49e-06	0.000225	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CAV1—ovarian cancer	3.47e-06	0.000224	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CAV1—ovarian cancer	3.46e-06	0.000223	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	3.46e-06	0.000223	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—KRAS—ovarian cancer	3.41e-06	0.000219	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ABCB1—ovarian cancer	3.38e-06	0.000218	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	3.35e-06	0.000216	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ESR1—ovarian cancer	3.35e-06	0.000215	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	3.34e-06	0.000215	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—YAP1—ovarian cancer	3.33e-06	0.000214	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—TYMS—ovarian cancer	3.32e-06	0.000214	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	3.32e-06	0.000214	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK1—ovarian cancer	3.32e-06	0.000214	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—ovarian cancer	3.32e-06	0.000214	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.31e-06	0.000213	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6ST—ovarian cancer	3.29e-06	0.000212	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.27e-06	0.00021	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—TYMS—ovarian cancer	3.24e-06	0.000209	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CG—ovarian cancer	3.23e-06	0.000208	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CD—ovarian cancer	3.2e-06	0.000206	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	3.2e-06	0.000206	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—ovarian cancer	3.17e-06	0.000204	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CG—ovarian cancer	3.16e-06	0.000204	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APC—ovarian cancer	3.16e-06	0.000204	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—NRAS—ovarian cancer	3.16e-06	0.000204	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CG—ovarian cancer	3.16e-06	0.000203	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—ovarian cancer	3.14e-06	0.000202	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—ovarian cancer	3.13e-06	0.000201	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ABCB1—ovarian cancer	3.11e-06	0.0002	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ABCB1—ovarian cancer	3.09e-06	0.000199	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—TYMS—ovarian cancer	3.06e-06	0.000197	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK3—ovarian cancer	3.03e-06	0.000195	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—TYMS—ovarian cancer	3.03e-06	0.000195	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—ovarian cancer	3.03e-06	0.000195	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CAV1—ovarian cancer	2.98e-06	0.000192	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HRAS—ovarian cancer	2.9e-06	0.000186	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK1—ovarian cancer	2.88e-06	0.000186	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—ovarian cancer	2.88e-06	0.000186	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—ovarian cancer	2.88e-06	0.000185	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.85e-06	0.000183	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	2.84e-06	0.000183	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CD—ovarian cancer	2.84e-06	0.000183	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB2—ovarian cancer	2.83e-06	0.000182	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.83e-06	0.000182	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CB—ovarian cancer	2.79e-06	0.00018	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MTOR—ovarian cancer	2.79e-06	0.00018	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CD—ovarian cancer	2.78e-06	0.000179	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CD—ovarian cancer	2.77e-06	0.000179	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—ovarian cancer	2.76e-06	0.000177	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—ovarian cancer	2.72e-06	0.000175	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CG—ovarian cancer	2.72e-06	0.000175	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—FASN—ovarian cancer	2.71e-06	0.000175	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—ovarian cancer	2.68e-06	0.000173	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CAV1—ovarian cancer	2.68e-06	0.000172	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.67e-06	0.000172	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HRAS—ovarian cancer	2.67e-06	0.000172	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ABCB1—ovarian cancer	2.64e-06	0.00017	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	2.62e-06	0.000169	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CAV1—ovarian cancer	2.61e-06	0.000168	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	2.59e-06	0.000167	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TYMS—ovarian cancer	2.59e-06	0.000167	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.58e-06	0.000166	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CASP3—ovarian cancer	2.57e-06	0.000165	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL2—ovarian cancer	2.56e-06	0.000165	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.56e-06	0.000165	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—AKT1—ovarian cancer	2.56e-06	0.000165	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—ovarian cancer	2.55e-06	0.000164	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—ovarian cancer	2.5e-06	0.000161	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—ovarian cancer	2.5e-06	0.000161	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	2.48e-06	0.000159	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CB—ovarian cancer	2.47e-06	0.000159	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.47e-06	0.000159	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CAV1—ovarian cancer	2.46e-06	0.000159	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	2.46e-06	0.000158	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CAV1—ovarian cancer	2.44e-06	0.000157	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CG—ovarian cancer	2.44e-06	0.000157	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—ovarian cancer	2.43e-06	0.000156	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MTOR—ovarian cancer	2.43e-06	0.000156	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	2.43e-06	0.000156	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CB—ovarian cancer	2.42e-06	0.000156	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTEN—ovarian cancer	2.41e-06	0.000155	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CD—ovarian cancer	2.39e-06	0.000154	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.38e-06	0.000153	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	2.35e-06	0.000151	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.33e-06	0.00015	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	2.33e-06	0.00015	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	2.32e-06	0.000149	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	2.28e-06	0.000146	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	2.25e-06	0.000145	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.24e-06	0.000144	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	2.23e-06	0.000144	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL2—ovarian cancer	2.23e-06	0.000143	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	2.22e-06	0.000143	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	2.22e-06	0.000143	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.19e-06	0.000141	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	2.18e-06	0.00014	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	2.17e-06	0.00014	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	2.16e-06	0.000139	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	2.15e-06	0.000139	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	2.15e-06	0.000138	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CD—ovarian cancer	2.14e-06	0.000138	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTEN—ovarian cancer	2.14e-06	0.000138	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	2.11e-06	0.000136	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	2.1e-06	0.000135	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.09e-06	0.000135	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTEN—ovarian cancer	2.09e-06	0.000134	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CAV1—ovarian cancer	2.09e-06	0.000134	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CB—ovarian cancer	2.08e-06	0.000134	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	2.06e-06	0.000133	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	2.04e-06	0.000132	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.04e-06	0.000131	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—ovarian cancer	2.01e-06	0.000129	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TYMS—ovarian cancer	2e-06	0.000129	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.99e-06	0.000128	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.97e-06	0.000127	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.96e-06	0.000126	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.96e-06	0.000126	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.96e-06	0.000126	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.9e-06	0.000122	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.89e-06	0.000122	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.87e-06	0.000121	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.87e-06	0.00012	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.87e-06	0.00012	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.85e-06	0.000119	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.82e-06	0.000117	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTEN—ovarian cancer	1.8e-06	0.000116	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.79e-06	0.000115	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.74e-06	0.000112	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.72e-06	0.000111	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.7e-06	0.00011	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.7e-06	0.00011	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.7e-06	0.00011	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.7e-06	0.00011	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.67e-06	0.000108	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.65e-06	0.000106	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTEN—ovarian cancer	1.62e-06	0.000104	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CAV1—ovarian cancer	1.61e-06	0.000104	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	1.61e-06	0.000104	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTEN—ovarian cancer	1.58e-06	0.000101	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.58e-06	0.000101	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—ovarian cancer	1.51e-06	9.7e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—ovarian cancer	1.51e-06	9.7e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTEN—ovarian cancer	1.49e-06	9.56e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	1.48e-06	9.51e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.47e-06	9.48e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTEN—ovarian cancer	1.47e-06	9.48e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.47e-06	9.44e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.46e-06	9.37e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—ovarian cancer	1.43e-06	9.2e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	1.39e-06	8.95e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	1.37e-06	8.8e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—ovarian cancer	1.31e-06	8.42e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.29e-06	8.3e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—ovarian cancer	1.27e-06	8.17e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTEN—ovarian cancer	1.26e-06	8.1e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—AKT1—ovarian cancer	1.23e-06	7.93e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	1.21e-06	7.77e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—AKT1—ovarian cancer	1.2e-06	7.75e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.14e-06	7.33e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.12e-06	7.23e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.11e-06	7.16e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.05e-06	6.74e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.04e-06	6.69e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—AKT1—ovarian cancer	1.04e-06	6.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTEN—ovarian cancer	9.71e-07	6.25e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—AKT1—ovarian cancer	9.31e-07	5.99e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—AKT1—ovarian cancer	9.09e-07	5.85e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	8.88e-07	5.71e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKT1—ovarian cancer	8.56e-07	5.51e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKT1—ovarian cancer	8.49e-07	5.46e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKT1—ovarian cancer	7.25e-07	4.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	6.85e-07	4.41e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKT1—ovarian cancer	5.6e-07	3.6e-05	CbGpPWpGaD
